Table 1.

Clinical characteristics of patients with HCLv

Patient no.Age (y)/sexMonths after diagnosisPrior treatment (response)Months after last therapyHCL count (cells/mm3)Spleen size (max, mm)
RG0143/M67Cladribine (CR × 16 mo)5429,700185
RG0262/M148Cladribine (PR × 37 mo)494218
RG0351/F16Cladribine (PR × 11 mo)15440236
RG0475/M9Cladribine (PD)6370280
RG0554/F14Cladribine (PR × 9 mo)124,300213
RG0659/F36None15,300174
RG0780/M3None3,130220
RG0870/M11Cladribine (PR × 5 mo), rituximab (PD), splenectomy (PD)1.515,0000a
RG0968/M5Rituximab (PD)228,000370
RG1075/F50Cladribine (PR × 2 mo), rituximab (SD), splenectomy (PD)15241,0000a
  • aMaximum (max) spleen diameter and weight, 271 mm, 6 kg (RG08); and 210 mm, 3.2 kg (RG10); before splenectomy.